Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Britain's GSK seeks U.S approval for rival to J&J's multiple myeloma drug

Stock MarketsDec 16, 2019 23:41
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

(Reuters) - GlaxoSmithKline (L:GSK) said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson (N:JNJ) and Genmab's Darzalex.

New data from the treatment, belantamab mafodotin, showed 30 of 97 patients experienced a reduction in their myeloma cells at the end of a mid-stage study, DREAMM-2.

The trial was testing belantamab mafodotin, also known as GSK2857916, in patients who had received four to seven prior other treatments, including J&J and Genmab's (CO:GMAB) blockbuster drug Darzalex.

Data earlier this month showed Darzalex cut the risk of death or worsening cancer by 37% in patients with multiple myeloma, a cancer of the white blood cells.

GSK has submitted a marketing application to the U.S. Food and Drug Administration (FDA) in the 2.5 mg/kg dose. If approved, belantamab mafodotin would be the first anti-B-cell maturation antigen (BCMA) agent available in the United States, the company said.

Belantamab mafodotin targets the BCMA protein in cells characteristic of multiple myeloma - an area of focus for many drugmakers.

The latest results are from the first of about 10 trials planned for belantamab mafodotin as GSK aims to soon show its benefits in earlier phases of treatment.

Axel Hoos, GSK's oncology research and development head, said the rate of response - or the number of patients that experience a reduction in myeloma cells – should go up with every earlier cycle of treatment.

"We are pretty confident that we can actually achieve the same (response rates) if not more and eventually even beat Darzalex in some settings," he said.

As early as next year, the British group aims to launch a trial where the drug is given to newly diagnosed multiple myeloma patients.

J&J and Genmab are expected to generate more than $4 billion in Darzalex revenues between them in 2020, according to the Refinitiv average analyst estimate.

Britain's GSK seeks U.S approval for rival to J&J's multiple myeloma drug
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email